AU2021360633A1 - Novel anti-cd47 antibodies and uses thereof - Google Patents

Novel anti-cd47 antibodies and uses thereof Download PDF

Info

Publication number
AU2021360633A1
AU2021360633A1 AU2021360633A AU2021360633A AU2021360633A1 AU 2021360633 A1 AU2021360633 A1 AU 2021360633A1 AU 2021360633 A AU2021360633 A AU 2021360633A AU 2021360633 A AU2021360633 A AU 2021360633A AU 2021360633 A1 AU2021360633 A1 AU 2021360633A1
Authority
AU
Australia
Prior art keywords
antibody
cell
cancer
immunologically active
active fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021360633A
Other languages
English (en)
Other versions
AU2021360633A9 (en
Inventor
Wei Cao
Bingshi GUO
Zhengyi WANG
Cong XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TJ Biopharma (Shanghai) Co Ltd
Original Assignee
I Mab Biopharma Co Ltd
I-Mab Biopharma US Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I Mab Biopharma Co Ltd, I-Mab Biopharma US Ltd filed Critical I Mab Biopharma Co Ltd
Publication of AU2021360633A1 publication Critical patent/AU2021360633A1/en
Publication of AU2021360633A9 publication Critical patent/AU2021360633A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2021360633A 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof Abandoned AU2021360633A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020120869 2020-10-14
CNPCT/CN2020/120869 2020-10-14
CNPCT/CN2020/122188 2020-10-20
CN2020122188 2020-10-20
PCT/CN2021/123892 WO2022078465A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2021360633A1 true AU2021360633A1 (en) 2023-06-15
AU2021360633A9 AU2021360633A9 (en) 2025-01-09

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021360633A Abandoned AU2021360633A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Country Status (12)

Country Link
US (1) US20230399400A1 (cg-RX-API-DMAC7.html)
EP (1) EP4229088A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023546277A (cg-RX-API-DMAC7.html)
KR (1) KR20230114745A (cg-RX-API-DMAC7.html)
CN (1) CN116348601A (cg-RX-API-DMAC7.html)
AU (1) AU2021360633A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198895A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005611A2 (cg-RX-API-DMAC7.html)
IL (1) IL302112A (cg-RX-API-DMAC7.html)
MX (1) MX2023004223A (cg-RX-API-DMAC7.html)
TW (1) TW202229351A (cg-RX-API-DMAC7.html)
WO (1) WO2022078465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200140565A1 (en) * 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
KR102366853B1 (ko) * 2017-11-10 2022-02-23 아이-맵 바이오파마 유에스 리미티드 Cd47 항체 및 사이토카인을 포함하는 융합 단백질
WO2020036977A1 (en) * 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
AU2019370754A1 (en) * 2018-10-31 2021-02-04 I-Mab Biopharma Us Limited Novel CD47 antibodies and methods of using same
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白

Also Published As

Publication number Publication date
TW202229351A (zh) 2022-08-01
EP4229088A1 (en) 2023-08-23
CA3198895A1 (en) 2022-04-21
CO2023005611A2 (es) 2023-05-29
US20230399400A1 (en) 2023-12-14
WO2022078465A1 (en) 2022-04-21
KR20230114745A (ko) 2023-08-01
JP2023546277A (ja) 2023-11-01
AU2021360633A9 (en) 2025-01-09
CN116348601A (zh) 2023-06-27
MX2023004223A (es) 2023-08-03
IL302112A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US11485782B2 (en) Anti-claudin 18.2 antibodies
US12458818B2 (en) Anti-trophoblast cell surface antigen 2 (TROP2) antibodies and antibody drug conjugates comprising same
JP2024026140A (ja) Lilrb2に対する抗体
JP5688433B2 (ja) 抗epha2抗体
WO2021047599A1 (en) Humanized anti-claudin 18.2 (cldn18.2) antibodies
CN117545779B (zh) 抗ctla-4抗体的用途
TW201819411A (zh) Pd-1之抗體及其用途
KR20200118065A (ko) 이중특이적 항원-결합 분자 및 이의 사용 방법
US20240103010A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
WO2022078465A1 (en) Novel anti-cd47 antibodies and uses thereof
US20250101120A1 (en) Antibodies specifically recognizing fasl and uses thereof
KR20180083313A (ko) Hiv 항체 조성물 및 사용 방법
WO2025119313A1 (en) Novel anti-cd47 antibodies and uses thereof
HK40091237A (en) Novel anti-cd47 antibodies and uses thereof
EP4606886A1 (en) Antibody combination specifically binding to trail or fasl, and bispecific antibody
HK40034257B (en) Anti-claudin 18.2 antibodies
HK40034257A (en) Anti-claudin 18.2 antibodies
WO2019183375A1 (en) Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
HK1126796A (en) Antibodies against insulin-like growth factor i receptor and uses thereof

Legal Events

Date Code Title Description
SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period